Senti Biosciences Announces $4.5M in Financing via Convertible Notes and Equity Commitment

Senti Biosciences disclosed two financing agreements totaling $4.5 million. The company completed a previously announced $2.0 million sale of Senior Secured Convertible Notes and entered into a new $2.5 million equity commitment letter with an affiliate of Celadon Partners, LLC. These agreements are in connection with a potential merger with a Celadon-affiliated entity.

Key Details

• Convertible Note Sale: On September 3, 2026, the company's subsidiary, Senti Holdings, Inc., completed the sale of $2.0 million in Senior Secured Convertible Notes to NSG BioInnovation Fund, L.P.
• Equity Commitment: On September 3, 2026, the company entered into an equity commitment letter with an affiliate of Celadon Partners for the purchase of $2.5 million in common stock. The purchase will occur around the time of the closing of the proposed merger.
• Strategic Context: These financing events are related to a potential merger where a Celadon-affiliated entity would merge with Senti Holdings. The transaction may also provide Senti's current stockholders with a contingent value right (CVR) of up to $60.0 million based on certain milestones for the SENTI-202 product candidate.